Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART Feasibility Pilot for Acute Severe Ulcerative Colitis
NCT05867329Phase 4Recruiting
- Start
- Sep 2023
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of upadacitinib in ulcerative colitis (UC) (9 arms). Primary endpoints: Adherence to intervention during first stage of therapy at Day 3, Adherence to intervention during second stage of therapy and 17 more. Started Sep 2023; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05867329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05867329.